Patents by Inventor Paul Beswick

Paul Beswick has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240108737
    Abstract: The present invention relates to multimers of polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. The invention also describes the multimerization of polypeptides through various chemical linkers and hinges of various lengths and rigidity using different sites of attachments within polypeptides. In particular, the invention describes multimers of peptides which are high affinity binders of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), particularly the spike protein S1 of SARS-CoV-2. The invention also includes pharmaceutical compositions comprising said polypeptides and to the use of said polypeptides in suppressing or treating a disease or disorder mediated by infection of SARS-CoV-2 or for providing prophylaxis to a subject at risk of infection of SARS-CoV-2.
    Type: Application
    Filed: January 10, 2022
    Publication date: April 4, 2024
    Inventors: Nicholas KEEN, Gemma MUDD, Katerine VAN RIETSCHOTEN, Katie GAYNOR, Liuhong CHEN, Maximilian HARMAN, Michael SKYNNER, Paul BESWICK, Mehdi AMOURA, Simone GIORGI, Giulia LATTANZI, Iain LINGARD
  • Publication number: 20240091368
    Abstract: The present invention relates to multimers of polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. The invention also describes the multimerization of polypeptides through various chemical linkers and hinges of various lengths and rigidity using different sites of attachments within polypeptides. In particular, the invention describes multimers of peptides which are high affinity binders of ACE2. The invention also includes pharmaceutical compositions comprising said polypeptides and to the use of said polypeptides in suppressing or treating a disease or disorder mediated by ACE2, such as infection of COVID-19 or for providing prophylaxis to a subject at risk of infection of COVID-19.
    Type: Application
    Filed: January 10, 2022
    Publication date: March 21, 2024
    Inventors: Nicholas KEEN, Katerine VAN RIETSCHOTEN, Liuhong CHEN, Maximilian HARMAN, Paul BESWICK, Paul BESWICK
  • Publication number: 20240083944
    Abstract: The present invention relates to multimers of polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. The invention also describes the multimerization of polypeptides through various chemical linkers and hinges of various lengths and rigidity using different sites of attachments within polypeptides. In particular, the invention describes multimers of peptides which are high affinity binders of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), particularly the spike protein S1 of SARS-CoV-2. The invention also includes pharmaceutical compositions comprising said polypeptides and to the use of said polypeptides in suppressing or treating a disease or disorder mediated by infection of SARS-CoV-2 or for providing prophylaxis to a subject at risk of infection of SARS-CoV-2.
    Type: Application
    Filed: January 10, 2022
    Publication date: March 14, 2024
    Inventors: Nicholas KEEN, Gemma MUDD, Katerine VAN RIETSCHOTEN, Katie GAYNOR, Liuhong CHEN, Maximilian HARMAN, Michael SKYNNER, Paul BESWICK, Mehdi AMOURA, Simone GIORGI, Giulia LATTANZI, Iain LINGARD
  • Publication number: 20240083945
    Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of the COVID-19 nucleocapsid protein (N-protein). The invention also includes pharmaceutical compositions comprising said polypeptides and to the use of said polypeptides in suppressing or treating a disease or disorder mediated by the COVID-19 nucleocapsid protein (N-protein), such as infection of COVID-19 or for providing prophylaxis to a subject at risk of infection of COVID-19.
    Type: Application
    Filed: January 10, 2022
    Publication date: March 14, 2024
    Inventors: Nicholas KEEN, Liuhong CHEN, Maximilian HARMAN, Michael SKYNNER, Paul BESWICK, Yuliya DEMYDCHUK
  • Patent number: 11912792
    Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of Nectin-4. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by Nectin-4.
    Type: Grant
    Filed: August 17, 2022
    Date of Patent: February 27, 2024
    Assignee: BicycleTx Limited
    Inventors: Paul Beswick, Liuhong Chen, Gemma Mudd, Peter Park, Katerine Van Rietschoten, Michael Rigby
  • Publication number: 20240018508
    Abstract: The present invention relates to a method for determining an extent of cyclisation of a peptide ligand displayed on a genetic display system, wherein the peptide ligand comprises a polypeptide covalently linked to a molecular scaffold at two or more amino acid residues, comprising the steps of exposing the polypeptide displayed on the genetic display system to the molecular scaffold, wherein said polypeptide comprises two or more peptide reactive groups on said two or more amino acid residues which form covalent bonds with the molecular scaffold at two or more scaffold reactive groups, to give the peptide ligand; removing unreacted molecular scaffold from the genetic display system; exposing the peptide ligand displayed on the genetic display system to a first probe, wherein the first probe binds to a first unconjugated reactive group on the peptide ligand; and measuring the first unconjugated reactive group on the peptide ligand.
    Type: Application
    Filed: October 2, 2020
    Publication date: January 18, 2024
    Inventors: Michael SKYNNER, James COOKE, Emma CRAWLEY, Liuhong CHEN, Gemma MUDD, Paul BESWICK
  • Publication number: 20230287047
    Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of Nectin-4. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by Nectin-4.
    Type: Application
    Filed: August 17, 2022
    Publication date: September 14, 2023
    Inventors: Paul BESWICK, Liuhong CHEN, Gemma MUDD, Peter PARK, Katerine VAN RIETSCHOTEN, Michael RIGBY
  • Publication number: 20230183291
    Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of ACE2. The invention also includes pharmaceutical compositions comprising said polypeptides and to the use of said polypeptides in suppressing or treating a disease or disorder mediated by ACE2, such as infection of COVID-19 or for providing prophylaxis to a subject at risk of infection of COVID-19.
    Type: Application
    Filed: May 14, 2021
    Publication date: June 15, 2023
    Inventors: Nicholas KEEN, Katerine VAN RIETSCHOTEN, Liuhong CHEN, Maximilian HARMAN, Michael SKYNNER, Paul BESWICK, Yuliya DEMYDCHUK
  • Publication number: 20230106511
    Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of penicillin-binding proteins (PBPs) more particularly PBP3. The invention also includes pharmaceutical compositions comprising said peptide ligands and to the use of said peptide ligands in suppressing or treating a disease or disorder mediated by bacterial infection or for providing prophylaxis to a subject at risk of infection.
    Type: Application
    Filed: February 26, 2021
    Publication date: April 6, 2023
    Inventors: Matthew BALMFORTH, Paul BESWICK, Liuhong CHEN, Mike DAWSON, Rachel DODS, Catherine ROWLAND, Michael SKYNNER, Katerine VAN RIETSCHOTEN
  • Publication number: 20230086865
    Abstract: The present invention relates to a polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the bicyclic peptides of the invention are conjugated to a carrier peptide in order to greatly enhance the bacterial cell killing activity. More particularly, the invention describes peptides which are high affinity binders of penicillin-binding proteins (PBPs), such as PBP3 and PBP3a. The invention also includes pharmaceutical compositions comprising said conjugates and to the use of said conjugates in suppressing or treating a disease or disorder mediated by bacterial infection or for providing prophylaxis to a subject at risk of infection.
    Type: Application
    Filed: February 26, 2021
    Publication date: March 23, 2023
    Inventors: Matthew BALMFORD, Paul BESWICK, Mike DAWSON, Rachel DODS, Catherine ROWLAND, Michael SKYNNER, Katerine VANRIETSCHOTEN, James WAGSTAFF
  • Publication number: 20230041661
    Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of IL-17. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by IL-17.
    Type: Application
    Filed: December 16, 2020
    Publication date: February 9, 2023
    Inventors: Paul BESWICK, Gemma MUDD
  • Publication number: 20230039677
    Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of IL-17. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by IL-17.
    Type: Application
    Filed: December 16, 2020
    Publication date: February 9, 2023
    Inventors: Paul BESWICK, Gemma MUDD
  • Publication number: 20230033370
    Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of IL-17. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by IL-17.
    Type: Application
    Filed: December 16, 2020
    Publication date: February 2, 2023
    Inventors: Paul BESWICK, Gemma MUDD
  • Publication number: 20230021419
    Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of IL-17. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by IL-17.
    Type: Application
    Filed: December 16, 2020
    Publication date: January 26, 2023
    Inventors: Paul BESWICK, Gemma MUDD
  • Publication number: 20230000847
    Abstract: The invention provides compounds of the formula (I): (I) wherein A1, A2, R2, R4, B1, B2, X, X1, n, a and b are as defined are defined in the specification, to pharmaceutical compositions comprising the compounds and the compounds for use as medicaments. The compounds potentiate AMPA receptor function and are expected to be useful in the treatment of central nervous system disorders, for example in the treatment of depressive disorders, mood disorders and cognitive dysfunction associated with neuropsychiatric disorders such as schizophrenia.
    Type: Application
    Filed: March 4, 2022
    Publication date: January 5, 2023
    Inventors: Simon WARD, Paul BESWICK, Lewis PENNICOTT, Tristan REUILLON, Irina CHUCKOWREE, Carolina VILLALONGA-BARBER, Roderick Alan PORTER
  • Patent number: 11453702
    Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of Nectin-4. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by Nectin-4.
    Type: Grant
    Filed: September 30, 2021
    Date of Patent: September 27, 2022
    Assignee: BICYCLETX LIMITED
    Inventors: Paul Beswick, Liuhong Chen, Gemma Mudd, Peter Park, Katerine Van Rietschoten, Michael Rigby
  • Publication number: 20220281918
    Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of penicillin-binding proteins (PBPs). The invention also includes pharmaceutical compositions comprising said peptide ligands and to the use of said peptide ligands in suppressing or treating a disease or disorder mediated by bacterial infection or for providing prophylaxis to a subject at risk of infection.
    Type: Application
    Filed: August 28, 2020
    Publication date: September 8, 2022
    Inventors: Katerine VAN RIETSCHOTEN, Paul BESWICK, Mike DAWSON, Matthew BALMFORTH, Michael SKYNNER, Liuhong CHEN
  • Patent number: 11396530
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: October 28, 2020
    Date of Patent: July 26, 2022
    Assignee: BICYCLETX LIMITED
    Inventors: Paul Beswick, Gemma Elizabeth Mudd, Kevin McDonnell, Gabriela Ivanova-Berndt, Katerine Van Rietschoten, David Witty, Michael Skynner
  • Patent number: 11298345
    Abstract: The invention provides compounds of the formula (I): (I) wherein A1, A2, R2, R4, B1, B2, X, X1, n, a and b are as defined are defined in the specification, to pharmaceutical compositions comprising the compounds and the compounds for use as medicaments. The compounds potentiate AMPA receptor function and are expected to be useful in the treatment of central nervous system disorders, for example in the treatment of depressive disorders, mood disorders and cognitive dysfunction associated with neuropsychiatric disorders such as schizophrenia.
    Type: Grant
    Filed: March 1, 2019
    Date of Patent: April 12, 2022
    Assignee: University College Cardiff Consultants Limited
    Inventors: Simon Ward, Paul Beswick, Lewis Pennicott, Tristan Reuillon, Irina Chuckowree, Carolina Villalonga-Barber, Roderick Alan Porter
  • Publication number: 20220089643
    Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of Nectin-4. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by Nectin-4.
    Type: Application
    Filed: September 30, 2021
    Publication date: March 24, 2022
    Inventors: Paul BESWICK, Liuhong CHEN, Gemma MUDD, Peter PARK, Katerine VAN RIETSCHOTEN, Michael RIGBY